David A. Learmonth
CTO
biochemistry
stemmatters
Portugal
Biography
He have Degree in Chemistry and PhD in Medicinal Chemistry from the University of Strathclyde, Scotland. Over 20 years drug research and development/managerial experience in the pharmaceutical industry with Rhône-Poulenc, GSK and Bial, contributing to the advancement of fifteen new molecules into preclinical/clinical phases, including the EMA/FDA approved antiepileptic drug Zebinix/Aptiom and the EMA approved anti-Parkinson drug Ongentys. Author of several hundred international patents and participated in over 20 due diligence inspections before regulatory approval, resulting in out-licensing agreements in Europe, US and Japan involving upfront and milestone payments in excess of 350M€.
Research Interest
pharmaceuticals new molecule into preclinical/clinical phases
